Table 2.
Association between adverse events associated with warfarin and prescriptions for warfarin and ACE inhibitors in different comparison periods
Comparison period (days after exposure)
|
No of physicians evaluated
|
Odds ratio (95% Cl)
|
|
---|---|---|---|
Warfarin use* | ACE inhibitor use* | ||
Bleeding analysis | |||
0-90 | 530 | 0.79 (0.62 to 1.00) | 1.13 (0.87 to 1.47) |
91-180 | 521 | 0.60 (0.46 to 0.79) | 1.16 (0.90 to 1.51) |
181-270 | 488 | 0.61 (0.46 to 0.81) | 1.11 (0.84 to 1.46) |
271-360 | 469 | 0.72 (0.54 to 0.97) | 1.06 (0.79 to 1.41) |
Stroke analysis | |||
0-90 | 704 | 0.95 (0.75 to 1.19) | 0.88 (0.70 to 1.11) |
91-180 | 664 | 1.05 (0.82 to 1.34) | 0.99 (0.78 to 1.26) |
181-270 | 656 | 1.22 (0.96 to 1.55) | 1.17 (0.92 to 1.50) |
271-360 | 621 | 1.23 (0.96 to 1.58) | 1.08 (0.84 to 1.40) |
Analyses adjusted for risk factors for stroke and bleeding as well as cardiology involvement in patient's care.